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Abstract
We tested 6 single nucleotide polymorphisms (SNPs) associated with obesity from genome wide
association studies for their association with physical activity (PA). Healthy European-American
women (n=265) and men (n=230) (23.5±0.3yr, 24.6±0.2kg•m-2) were genotyped for MC4R
(rs17782313), FTO (rs9939609), TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and
KCTD15 (rs11084753), and completed the Paffenbarger PA Questionnaire. We examined gene
interactions by summing the number of obesity effect alleles. RESULTS: Normal weight subjects with
MC4R T expended 1981.2±741.7kcal∙wk-1 less than non-carriers in total PA (p=0.008), 1825.9±650.2
kcal∙wk-1 less in sports/recreation (p=0.027), and 1231.3±552.7 kcal∙wk-1 less in vigorous PA (p=0.005).
Subjects with TMEM18 C expended 1216.5±356.3kcal∙wk-1 less than non-carriers in moderate PA
(p=0.001). Overweight men homozygous for FTO T expended 871.4±397.1kcal∙wk-1 less than A carriers
in vigorous PA (p=0.031). Subjects homozygous for SH2B1 G spent 4.8±1.9hr∙wk-1 less than noncarriers in moderate PA (p=0.013), and 5.6±2.2hr∙wk-1 more in light PA. Women homozygous for
NEGR1 G spent 7.6±2.7hr∙wk-1 less than A carriers in moderate PA (p=0.006). Overweight subjects
homozygous for KCTD15 A spent 14.2 ±4.8hr∙wk-1 more than G carriers in sitting (p=0.004). Men with
5-6 (n=173) obesity effect alleles expanded 1082.3±447.2kcal∙wk-1 more in sports/recreation (p=0.049)
and 663.8±418.1kcal∙wk-1 more in vigorous PA (p=0.049) than men with 7-10 (n=131), with similar
non-significant trends noted for 1-4 (n=153) obesity effect alleles (p>0.05). CONCLUSION: The
genotype differences in energy expenditure that equate to 11-25 lb∙yr-1 have important implications for
weight maintenance. The mechanisms explaining these associations appear to have a common central
neural influence that should be explored further.

Chapter 1 - Introduction
Background and Significance
Obesity is an epidemic in the Unites States (U.S.) with 69% of adults being either overweight
[body mass index (BMI)>25kg∙m-2] or obese (BMI>30kg∙m-2). Between 1980 and 2010 in the
U.S., the prevalence of the obesity within the adult population has grown from 15.0% to 35.7%
(31). If the current trends proceed at this pace, by 2030, all 50 states could have adult obesity
rates of at least 44%, 39 states would have rates of 50% or more, and 13 states would have more
than 60% of adults with obesity (81). Obesity is associated with significant increases in both
mortality and morbidity (3). It is estimated that there are 4 million deaths attributable to obesity
in the U.S. each year (57). The most important and common comorbidities resulting from obesity
are hypertension, type 2 diabetes mellitus, hyperlipidemia, and coronary artery disease (38). In
addition, abdominal obesity is associated with metabolic syndrome (23). Other comorbidities of
obesity are asthma, non-alcoholic fatty liver disease, polycyclic ovary disease, gall bladder
disease, and several cancers (5, 9, 10, 16, 33, 59, 65, 68). The U.S. medical service system
spends $147 billion per year for direct medical costs related to overweight and obesity, which
accounts for 9% of the total U.S. health-care expenditure (28). According to a national survey
data (National Health and Nutrition Examination Study) from 1970s and 2004, by 2030, the total
health-care costs attributable to obesity and overweight are projected to $ 861-957 billion
accounting for 16–18% of total U.S. health-care expenditure (83).
To mitigate this public health epidemic, the American College of Sports Medicine
(ACSM) (25), American Heart Association (AHA), and the U.S. Department of Health and
Human Services (79) advocate physical activity (PA) for weight loss and successful long-term
weight maintenance. Habitual PA is bodily movement involving major muscle groups resulting
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in caloric expenditure (17). The ACSM recommends 150 to 250 min∙wk-1 of moderate intensity
PA for weight loss, and even greater amounts of PA (>250 min∙wk-1) for weight maintenance
(25). The U.S. Department of Health and Human Services (62) examined 4 randomized trials
that investigated the influence of aerobic training on weight change. These studies (37, 55, 70,
73) ranged in duration from 8 to 16 months, and the PA levels ranged from 180-360 min·wk-1
performed at moderate to vigorous intensity. Subject included men and women from 40-75 years
whose weight ranged from normal to overweight and obese. Typical weight losses were 2.2 to
6.6 lb. Of note, although the National Heart, Lung, and Blood Institute (NHLBI) Guidelines (62)
recommend a minimum weight loss of 10%, beneficial improvements in chronic disease risk
factors have been reported with as little as 2–3% of weight loss (24, 30, 43, 77). In addition,
evidence of a dose-response relationship was clear; those doing the greatest amount of PA
achieved the greatest weight losses.
One of the significant benefits of PA lies in its role in successful long-term weight
maintenance after initial weight loss (85). Wing et al. (85) examined 4,000 members of the
National Weight Control Registry who had lost an average of 33 lbs and maintained the weight
lost for more than 5 years. To maintain their weight loss, members reported engaging in high
levels of PA (approximately 1 h/d); eating a low-calorie, low-fat diet; eating breakfast regularly;
self-monitoring weight; and maintaining a consistent eating pattern across weekdays and
weekends. As shown, scientific evidence has proven that PA is effective in weight loss and
weight maintenance after weight loss, and thereby health agencies and government endorse PA
as a non-pharmaceutical treatment to address the current obesity epidemic.
Paradoxically, most people do not meet the recommended amount of PA level despite of
well-known health benefits of PA. Less than half of U.S. adults meet the minimum
2

recommendations for PA as set by the ACSM and AHA (25). Moreover, about 24% of
Americans do not participate in any leisure time PA (17). This low level of PA and sedentary
lifestyle is also a serious public health issue. According to World Health Organization (WHO)
(86), physical inactivity has been identified as the fourth leading risk factor for global mortality
(6% of deaths globally), followed by high blood pressure (13%), tobacco use (9%) and high
blood glucose (6%). Thus, identifying the determinants of the PA participation is critical, as it
will yield relevant information to address the public health burdens of physical inactivity and
obesity. Notably, understanding why people are physically active or inactive can contribute to
evidence-based planning of public health interventions because effective programs targets factors
known to cause inactivity (64).

Purpose of the Study
One of the longest debates in Western intellectual history is the relative influence of genetic and
environmental factors on human behavioral differences, the so-called nature-nurture debate (22).
Habitual PA, which also is a behavior that varies among individuals, is regulated or governed
primarily by environmental factors, genetic factors, and interaction between both (8). Research
into correlates (factors associated with) and determinants (those with a causal relationship) of PA
has burgeoned in the past two decades, and it has shown that PA is influence by numerous
factors such as psychological factors (e.g. cognition, beliefs, and motivation), built environment
(e.g. availability of facilities), social environment (e.g. seeing others active), and biological
factors (e.g. genetic factor). Recent studies have identified genetic factors contributing to the
propensity to be physically active (48-50, 78). Yet, little is known about potential genetic
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regulators of PA. Therefore, the purpose of this study is to identify genetic variants that
associate with PA that have already been identified to associate with obesity.

Genetics of Obesity and Physical Activity
Obesity occurs most often when energy intake chronically exceeds energy expenditure (6).
Similarly, as one of the expected phenotypic outcomes of being physically inactive is gaining
weight, obesity genes may be reasonable candidate genes to investigate whether they associate
with PA. Until recently, obesity was considered to be the outcome that is solely generated from
obesogenic environment in which encourages excessive caloric intake and a sedentary life style
(6). However, there are multiple lines of evidence reporting the genetic predisposition on the
development of obesity (11, 13, 20, 52, 53, 61, 71, 74). The studies report that the heredity
accounts for 37-78% of the variance in several measures of body composition including BMI,
weight, and waist circumference. Bouchard (12) has categorized obesity genes in 5 groups in
terms of biological function of the proteins the genes code for. They are, 1) a thrifty (low
metabolic rate), 2) a hyperphagic (impaired appetite), 3) a low lipid oxidation (burn less fat), 4)
an adipogenesis (accumulate more fat), 5) and a sedentary (physically inactive) (12).
The sedentary gene codes for a protein that functions to modulate our propensity to be
less active and sedentary, and in turn predisposes the individual to obesity (12). Twin and family
studies have shown that genetic factors contribute to variation in reported daily PA levels, with
heritability estimates ranging from small (h2 <30%) (29, 32, 56, 69) to moderate (h2=30–65%),
(14, 15, 26, 40, 54) to high (h2=78%) (1). The large heterogeneity might be explained by the
large ranges in age within and between studies, the accuracy with which daily PA is assessed,
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and study design (39). Regardless, these studies suggest the genetic influence on PA
participation.
All humans have almost the same sequence of 3 billion DNA bases (A,C,G, or T)
distributed between their 23 pairs of chromosomes. But at certain locations of nucleotide bases
there are mutations, and these variations are called single nucleotide polymorphism (SNP). To
classify a variation as a SNP it should occur in at least 1% of the population. Although this
mutation does not necessarily express functional phenotype, SNPs are responsible for over 80%
of the variation between two individuals. Accordingly, SNPs are often used to identify
association between genetic variants (i.e. SNP) and interest of phenotype (i.e. BMI or PA).
Since PA is a critical component of energy balance, it is not surprising that many of the
genetic variants associated with obesity have also been associated PA. Previously, Walsh et al.
(82) reported leptin and leptin receptor genetic variants, which are renowned obesity genes that
initiated the research in genetics of obesity (87), associate with habitual PA among EuropeanAmerican adults (men=111, women=131, 23.4 ± 5.4 yr, 24.4 ± 4.6 kg·m-2) in Functional Single
Nucleotide Polymorphisms Associated with Human Muscle Size and Strength (FAMuSS, NIH
R01 NS40606-02) cohort. Leptin is an adipocyte-derived cytokine that can act in the brain to
suppress feeding and maintain energy homeostasis. Similarly, Fat mass and obesity-associated
gene (FTO; rs9939609) also has been shown to associate with PA as well as other obesity
phenotypes (i.e. BMI, weight, waist circumference) (34, 36). Cecil et al. (18) examined if FTO
(rs9939609) associates with adiposity, food intake, and energy expenditure in 71 Scottish
children, 4 to 10 years of age, and observed children with the A allele being more physically
active compared to non-carriers. As shown, it is evident that PA is inheritable and SNPs
associated with obesity are also likely to associate with PA. Nonetheless, it still remains largely
5

unknown how the protein products from these genes affect PA level. What researchers are
speculating from functional studies in PA is that these genes may affect PA level via neural
influence on brain.
Charney et al., noted that genes particularly prevalent in the human brain are likely
relevant for a good deal of human behavior (19). Thus, we can speculate that obesity genes that
code for proteins that are expressed in brain or neural pathways may govern certain behavior (e.g.
eating or PA) that predisposes individuals to obesity. In the same way, evidence from human and
animal studies (42, 46, 47, 76) indicates that intrinsic biological processes such as central
nervous system (CNS) mechanisms might regulate daily PA. That is, reward systems,
particularly the dopaminergic system, will be activated in individuals with above-average
exercise abilities, those who crave PA, and those who feel rewarded by accomplishing PA (8).
Dopamine functions in the control of motor movement (63), reward (66), learning, motivation
(58), and emotion (67). As the dopamine system is involved in motivating and rewarding
behavior that involves motor control, it would be a probable candidate biological system to
modulate voluntary PA. As such, PA candidate genes might be part of the reward systems (21) in
brain, and thereby studies that examined the regulation of PA have mainly focused on genes that
constitute the dopaminergic pathway (4, 41, 88). Taken together, obesity genes that have impact
on the dopaminergic pathway would be biologically plausible to associate with PA.
In 2012, Fall et al. conducted systematic review of SNPs reported to associate with
obesity phenotypes in GWAS (27). They reported 99 genetic variants that showed association
with obesity phenotypes in GWAS. Among 99 SNPs, FAMuSS study had genotype information
for 6 SNPs: FTO (rs9939609), Melanocortin 4 receptor (MC4R; T2745C; rs17782313),
Transmembrane protein 18 (TMEM18; rs6548238), Neuronal growth regulator 1 (NEGR1;
6

rs2815752), Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; rs7498665), and
Potassium channel tetramerisation domain containing 15 (KCTD15; rs11084753).
Willer et al. measured the expression of the genes nearest to their best SNP association
signals in a panel of different human tissues in order to provide additional data on where these
genes may function. They found that all genes were highly expressed in the brain and/or
hypothalamus where energy homeostasis is regulated. It is noteworthy that all six SNPs in our
study are categorized as hyperphagic genes (impaired appetite) according to Bouchard’s
classification as they were all previously reported to associate with eating behavior (7, 18, 45,
60). To date, there are no studies that examine if NEGR1, KCTD15, SH2B1, and TMEM18
associate with PA in humans. However, NEGR1 and its association with PA have been examined
with mice (44). Taken together, the fact that all SNPs are expressed in hypothalamus and
previous association with behavior that affects energy balance (i.e. eating) provides biological
rationale that these SNPs would likely to associate with PA, which is another form of behavior
that can affect energy imbalance and predispose individual to obesity.
In summary, despite the critical role of PA in weight loss and weight maintenance, little
is known about specific genes that affect an individuals’ habitual PA level. However, previous
studies indicate that several genes, such as LEPTIN and FTO, identified to be associated with
obesity have also been associated with PA. Further, genetic variants associate with behavior
related to obesity (e.g. eating or PA) are likely to expressed in brain. Thus, obesity-related
genetic variants that are expressed in neural pathway would be biologically plausible candidate
genes to investigate their association with PA.

Specific Aim and Hypothesis
7

As shown many of the genes identified to be associated with overweight and obesity have also
been associated with PA (18, 82). To date, there are 99 genetic variants reported to be associated
with the obesity phenotype in genome wide association studies (GWAS) (27). The methods used
in the proposed research are based on the ‘Functional Single nucleotide polymorphisms
Associated with Human Muscle Size and Strength (FAMuSS, NIH R01 NS40606-02)’ dataset.
Therefore, the specific aim of present study is to examine 99 genetic variants identified to be
associated with overweight and obesity in GWAS and their associations with PA in FAMuSS
cohort. We hypothesize that SNPs associated with overweight and obesity also associate with
PA and these include FTO (rs9939609), MC4R (rs17782313), TMEM18 (rs6548238), SH2B1
(rs7498665), KCTD15 (rs11084753), NEGR1 (rs2815752). Although GWAS have shown strong
associations between obesity and gene loci (34, 51, 72, 84), these loci explain no more than 2%
of the individual variation in the susceptibility of obesity (84). Therefore, the secondary aim of
present study is to assess the overall effect or gene-gene interaction status of 6 SNPs on PA level.
In order to assess the epistatic or gene-gene interactions on habitual PA and BMI, we created a
genotype combination score based upon previous GWAS obesity effect alleles reported in the
literature (27)). We hypothesize that as the number of obesity effect allele increase, PA level
would decrease and BMI would increase in a dose response manner.

Limitations
This study has several limitations. Habitual PA is a complex behavior that is likely influenced by
psychological factors, social and built environment, other clinical information, and many genes
other than our six SNPs through multiple pathways (8). Also, this study was not designed to
obtain mechanistic data. Additionally, PA data were collected via questionnaire, thus exposing
8

the possibility of subject recall or social desirability bias. However, the Paffenbarger PA
questionnaire has been widely validated in similar populations to the present study and is
considered an accurate method of leisure time PA in adults (2).

Strengths
This investigation is a subset of the FAMuSS study which is the largest study that has
investigated candidate genes associated with muscle performance, and the first study to
specifically investigate obesity-related SNPs associations with PA (75). Furthermore, FAMuSS
meets the criteria outlined by Hagberg et al. (35) that are necessary for conducting exercise
genomics studies including a large sample size, a well-structured exercise intervention with
stringent assessment of phenotypes, and quality control of genotyping. In addition, heritability of
PA varies across the lifespan. PA is more heritable for young adults and tends to decrease with
age (80). Therefore, as ~75% of the FAMuSS subjects age ranged from 18 to 25, it is likely to
exhibit a high level of heritability.

Significance of the Study
Despite its crucial role in weight reduction, the genetic basis for PA remains largely unknown. If
we find significant genetic influences on PA, we will prove our hypothesis that PA associates
with SNPs associated with overweight and obesity. As we are one of the few studies examining
the genetic basis of PA, this study can yield crucial data for future investigation of the genetic
basis of PA. Genotype may influence PA, yet clinicians still use a generic approach in
recommending PA to treat obesity. In this sense, our findings will be an important step toward
providing clinicians with new knowledge about the genetic and biological basis of PA.
9
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Chapter 2 – Literature Review
Introduction
Approximately 30 - 78% (1, 10, 11, 19, 29, 44) of the variation in habitual physical activity
(PA) is explained by genetic factors. Research has identified specific genetic polymorphisms that
may contribute to this variation. Genetic variation primarily results from common single
nucleotide polymorphisms (SNPs). A SNP is a mutation that alters a small part of a gene,
specifically a single base, and this polymorphism is common in at least 1% of the population.
There are an estimated 12 million SNPs in the human genome which account for 90% of all
human genetic variation. Although not all the SNPs confer a functional difference, many SNPs
are reported to predispose individuals to a certain disease or trait, and thereby SNPs are often
used to identify associations between genetic variants (i.e. SNP) and interest of phenotype (i.e.
weight or PA).
The purpose of present study is to identify the SNPs that associate with PA in the
‘Functional SNPs Associated with Human Muscle Size and Strength (FAMuSS, NIH R01
NS40606-02)’ dataset, where the sub-set of population (n=492) were genotyped and completed
Paffenparger PA Questionnaire (PPAQ). Previously, Walsh et al. (64) reported leptin and leptin
receptor genetic variants, which are renowned obesity genes that initiated the research in genetics
of obesity (67), associate with habitual PA among European-American adults in FAMuSS cohort
(men=111, women=131, 23.4 ± 5.4 yr, 24.4 ± 4.6 kg·m-2). Leptin is an adipocyte-derived
cytokine that can act in the brain to suppress feeding and maintain energy homeostasis. Likewise,
as one of the expected phenotypic outcomes of being physically inactive is gaining weight, it is
not surprising that obesity genes also associate with PA levels (13, 31, 43). In fact, Bouchard has
classified obesity genes into 5 categories (6). They are, 1) a thrifty (low metabolic rate), 2) a
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hyperphagic (impaired appetite), 3) a low lipid oxidation (burn less fat), 4) an adipogenesis
(accumulate more fat), 5) and a sedentary (physically inactive). As shown sedentary genotype is
classified as one of the obesity genes, and thereby genetic variants reported to associate with
obesity may also associate with PA. Therefore, present study investigated SNPs reported to
associate with obesity phenotypes in Genome-Wide Association Study (GWAS) in order to
identify sedentary genotype in FAMuSS cohort. To date, 99 SNPs are reported to associate with
obesity phenotype in GWAS, and FAMuSS sub-study had genotype information for 9 SNPs
among 99 SNPs. However, 3 of the SNPs were excluded as they were not consistent with HardyWeinberg equilibrium, and total 6 SNPs were selected for candidate SNPs. They are
Melanocortin 4 receptor (MC4R; T2745C; rs17782313), Transmembrane protein 18 (TMEM18;
rs6548238), Fat mass and obesity-associated gene (FTO; rs9939609), Neuronal growth
regulator 1 (NEGR1; rs2815752), Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala;
rs7498665), and Potassium channel tetramerisation domain containing 15 (KCTD15;
rs11084753).
Among the 6 SNPs, FTO (rs9939609) and MC4R (rs17782313) are reported to associate
with PA (13, 32, 43) in human. To date, there are no studies that examine if TMEM18
(rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 (rs11084753) associate
with PA in humans. However, Negr1 and its association with PA have been examined with mice
(36).

Biological Basis of Habitual Physical Activity
Obesity genes expressed in brain and their biological plausibility to associate with PA
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Charney et al. (14) denotes that genes particularly prevalent in the human brain are likely
relevant for a considerable part of human behavior. It is noteworthy that hyperphagic genotype
and sedentary genotype, that Bouchard categorized, are the obesity genes that are expressed in
brain. Thus, we can speculate that obesity genes that code for proteins expressed in the brain or
neural pathways may govern behaviors (i.e. eating or PA) that predispose individuals to obesity.
In fact, Lenard et al (38), who has extensively examined central and peripheral regulation of
food intake and PA, propose that fundamental desire to engage in PA stems from food foraging
behavior to prevent oneself from famine as a survival mechanism. According to Lenard et al.,
one of the fundamental neurological paradigms involved is finding a good food source,
remembering it, and finding it again. In other words, large portions of the nervous system of
animals and humans, including the cortex, basal ganglia, and the limbic system, are concerned
with the procurement of food as a basic and evolutionarily conserved survival mechanism to
defend the lower limits of adiposity. For instance, a key structure is the hippocampal formation,
known to be involved in the formation, storage, and recall of spatial and other memories (38)
(Figure 1).
Taken together, there may be inter-connection of neural pathway between energy intake
and PA energy intake. Both genes code for proteins that function in brain to induce certain
behavior that impact energy homeostasis. Thereby, hyperphagic obesity gene may be biological
plausible to associate with PA. With this in mind, it is noteworthy that NEGR1, KCTD15, and
SH2B1are categorized in the hyperphagic genotype according to Bouchard’s classification as
they were all previously reported to associate with eating behavior (3, 61).

Dopaminergic pathway and physical activity
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Within the central nervous system (CNS), neurotransmitters, peptides, and hormones interact to
establish a balance between energy intake and energy expenditure, resulting in body weight
regulation and homeostasis (45). An abundance of recent research (33, 35, 40, 41, 54)
investigating the biological pathways that govern PA participation indicates that the
dopaminergic pathway may play a key role. Of note, dopamine is a neurotransmitter that
functions in the control of motor movement (58), reward (59), learning, motivation (48), and
emotion (60).
The dopaminergic pathway is purported to regulate voluntary PA because of its central
role in regulating motor movement (58) and motivational behaviors (48). Wheel running
behavior is considered to be a measurement of voluntary PA in rodents, which is defined as
purposeful movements that expend a significant amount of energy (35). Data from
pharmacological experiments suggest that dopamine function in hyperactive mice is impaired
(55, 56). Rhodes et al. (55) measured acute drug responses (cocaine) of mice that had been
selectively bred for increased running-wheel activity. They found that psycho-stimulants such as
methylphenidate (56) and cocaine (55), which stimulate locomotor behavior and wheel running
in control mice, decreased wheel running in hyperactive mice. The authors concluded that the
results suggest an association between genetically determined hyperactive wheel-running
behavior and dysfunction in the dopaminergic neuromodulatory system. Additionally, Knab et al.
(33) investigated differences in central mRNA expression of seven dopamine genes (Drd1, Drd2,
Drd3, Drd4, Drd5, and tyrosine hydroxylase) between highly active C57/LJ (n=17) male mice
and less active C3H/HeJ (n=20) male mice. They found that the high-activity C57L/J strain has
lower expression levels of dopamine D1 receptor and tyrosine hydroxylase (an indicator of
dopamine production) than the low-activity C3H/HeJ strain (34). Such results raise the
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possibility that specific alterations in the dopaminergic pathway may be associated with
differential engagement in voluntary PA.
Dopamine deregulation has also been postulated to contribute to the development of
obesity and binge eating, which again supports previously noted biological plausibility of
hyperphagic genotype to associate with PA. Data have illustrated that alterations in the D2
dopamine receptor are linked to increased reward sensitivity in obese and binge eating
individuals (16). Likewise, research examining obesity prone rats revealed dopamine
deficiencies in the nucleus accumbens and dorsal striatum that were directly linked to
hyperphagia (impaired appetite) and increased body mass (22). Also, dopamine D4 receptors are
associated with binge eating in individuals with depression or bulimia nervosa (28, 39). In
addition, dopamine transporter knockout mice that show chronically elevated tissue dopamine
display increased goal-directed behavior for food reward (9).
In summary, dopaminergic deregulation is associated with the expression of PA, eating
behavior, and obesity-related phenotypes. Therefore, obesity genes that have impact on the
dopaminergic pathway would be biologically plausible to associate with PA as well.

Literature Review
Systematic search method
In this review of the literature, we aimed to include all studies with one or more of the
following outcomes: gene, SNPs, exercise, and PA. We performed a PubMed Search entering the
following search terms: ("Fat mass and obesity-associated gene" OR FTO OR rs9939609 OR
"Melanocortin 4 receptor" OR MC4R OR rs17782313 OR "Neuronal growth regulator 1" OR
NEGR1 OR rs2815752 OR KCTD15 OR rs11084753 OR SH2B1 OR rs7498665 OR
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"Transmembrane protein 18" OR TMEM18 OR rs6548238) AND ("physical activity" OR PARQ
OR PAR-Q OR "physical activities" OR "physically active" OR exercise OR exercises OR
walking OR locomotor OR "activities of daily living"). This search yielded 122 hits. If many
literature exists, the population characteristics emulate the FAMuSS cohorts (European
American, 23.5 ± 0.3 yr, BMI: 24.6 ± 0.2) were prioritized for review. These prioritization
criteria for selecting literature included adults 18 to 65 years; peer-reviewed journal articles
published in English; main topic of the article must be ‘genetic variants and PA level’; lastly,
systematic review recruited most subject number were prioritized. However, if no articles were
found within human, animal study that examined locomotors activities were reviewed. If
numerous animal study exists in animal studies, comparison between knock out animal for target
gene and control group were prioritized over the animal studies that compared control group and
protein administered group, as primary focus of preset study is on the gene than protein.
In the literature review, SNPs that showed association with PA were reviewed in the first
section: FTO (rs9939609) and MC4R (rs17782313). In the second section, SNPs that does not
have previous literature in PA were more extensively reviewed related to its biological
plausibility to associate with PA: TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1
(rs7498665), and KCTD15 (rs11084753). In each SNPs, basic information of the gene and
protein were reviewed. Then, we introduced SNPs’ association with obesity phenotype in
FAMuSS cohort. Subsequently, SNPs’ associations with PA phenotype in previous literature
were reviewed. Finally, SNPs’ biological plausibility to associate with PA was reviewed via
introducing literature that reports SNP and/or proteins’ expression in neural pathway, association
with energy intake, and implication on dopaminergic pathway.
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Genetic variants associate with obesity and physical activity
Fat mass and obesity-associated gene (FTO T>A; rs9939609)
FTO (rs9939609) is located on the 1st intron of chromosome 16q12.2. Frayling et al.
reported FTO was mostly expressed in the brain, specifically the hypothalamus (20, 63). Jia et al.
(26), reported that FTO protein has oxidative demethylation activity targeting the abundant N6methyladenosine (m6A) residues in RNA in vitro. In addition, they showed the partial colocalization of FTO with nuclear speckles, which supports the notion that m6A in nuclear RNA is
a major physiological substrate of FTO. Nonetheless, this proposed function of FTO provides no
immediate clues regarding the molecular-physiological mechanism by which this gene might
affect adiposity. Therefore, how the demethlase activity of FTO is integrated into the complex
network of energy metabolism control remains the object of intense scientific investigation
In 2010, Orkunoglu-Suer et al. (47) examined MC4R (rs17782313), FTO (rs9939609),
TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 (rs11084753) in
FAMuSS cohort (men=321, women=475, 23.1 ± 5.5 yr, 24.4 ± 4.6 kg·m-2) that undertook 12week resistance-training program with its association with BMI and subcutaneous fat.
Investigators choose theses SNPs because they were newly identified SNPs reported by the
Genetic Investigation of ANthropometric Traits (GIANT) consortium. Of note, the GWA metaanalysis that GIANT consortium conducted in 2009 by Willer et al. is the largest GWA metaanalysis conducted to date. Orkunoglu-Suer et al. reported difference in subcutaneous fat volume
in men carrying FTO (rs9939609) A alleles (AT/AA: n = 83; −798.35 ± 2,624.30 mm3 vs. TT: n
= 47; 9,435.23 ± 3,494.44 mm3; P = 0.02), and it explained 4.1% of the phenotype in men.
Cecil et al. (13) examined 2726 Scottish children, 4 to 10 years of age, who underwent
genotyping for FTO (rs9939609). A subsample of 75 children was examined for possible
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association of the FTO (rs9939609) with energy expenditure. They measured total energy
expenditure by isotope dilution, resting metabolic rate by indirect calorimetry, and PA was
calculated as subtracting resting metabolic rate from total energy expenditure. Total energy
expenditure was significantly greater in carriers of the A allele than in non-carriers, with a
difference of 1160 kJ (p=0.009). Resting energy expenditure was 349 kJ greater in children who
carried the A allele than in non-carriers (p=0.03); however, inclusion of body mass or lean body
mass as a covariate in the regression model abolished the association between genotype and
resting energy expenditure (p=0.216). PA-related expenditure was higher for A allele carriers
compared to non-carriers, with a difference of 1103 kJ (p=0.02). Therefore, the investigators
concluded that the observed difference in total energy expenditure between the genotype groups
was primarily derived from the difference in PA-related expenditure rather than resting
metabolic rate.
Tung et al. (63) reported that FTO mRNA overexpression associates with increased
levels of the dopamine regulatory enzyme tyrosine hydroxylase. Interestingly, Knab et al. (34)
reported that low tyrosine hydroxylase associate with hi PA level in inbred mice. Although it
remains unclear how RNA demethylation of FTO may have affected tyrosine hydroxylase
production, these findings supports findings of Cecil et al. that FTO (rs9939609) may associate
with PA level.
Melanocortin 4 receptor gene (MC4R T2745C; rs17782313)
The melanocortin 4 receptor gene (MC4R) is located on a single exon on chromosome
18q22. The melanocortin ‘‘system’’ can be defined as a neural circuit comprised of cells
expressing either pro-opiomelanocortin (POMC)-derived melanocortin receptor (MCR) agonists,
or the melanocortin antagonist agouti-related peptide (AgRP), as well as the MCR-expressing
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cells that are targets of these neurons. Foremost of the melanocortin-mediated functions is energy
balance regulation as a result of MCR signaling within hypothalamic and hindbrain nuclei. The
MC4R, a 7-transmembrane G-protein coupled receptor, is expressed on the surface of neurons
throughout the brain and in high proportion within the hypothalamus, hippocampus, and
hindbrain (15). MC4R can be directly activated via adrenocorticotropic hormone (ACTH) or aof melanocyte-stimulating hormone (MSH), or inhibited by AgRP, via release from terminals of
POMC or AgRP/NPY axonal projections from the ARC (15).
Orkunoglu-Suer et al. (47) also examined MC4R (rs17782313) in FAMuSS cohort with
its association with obesity phenotype. They reported that the MC4R (rs17782313) was
associated with BMI in females using a dominant model (CC/CT: n=174; 24.70±0.33 kg/m2, TT:
n=278; 23.41 ± 0.26 kg/m2, p=0.003), and it explained 1.9% (p=0.002) of the phenotype.
In 2005, Loos et al. (43) examined whether sequence variants in genes encoding
neuropeptides and receptors in the arcuate and paraventricular nucleus of the hypothalamus
contribute to variations in PA level in the QFS. They genotyped SNPs in MC4R, MC3R,
neuropeptide-Y (NPY), neuropeptide-Y Y1 receptor (NPY Y1R), cocaine- and amphetamineregulated transcript (CART), agoutirelated protein (AGRP), and pro-opiomelanocortin (POMC)
genes in 669 subjects (52±3.4 yr; offspring: 28±8.7 yr). In a 3-day activity diary, the subjects
recorded their dominant activity every 15-min period of the day. Each activity was categorized
into one of nine activity classes, ordered by increasing energy expenditure level (based on the
metabolic equivalent), and was scored accordingly from 1 to 9, with 1 equating to sleep and 9
equating to vigorous-intensity activities. Subjects carrying the homozygous MC4R (rs17782313)
T allele reported lower PA scores than those with the CC and CT genotypes (CC: 220±20 vs CT:
200±20 vs TT:165±24, p=0.005) . The effect was most pronounced in adults without obesity
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(BMI<30kg·m-2) (CC: 223±19 vs CT: 185±19 vs TT:158±25, p=0.004) and young adults
(offspring) (CC: 217±16 vs CT: 172±17 vs TT:121±24, p=0.007). Investigators concluded DNA
sequence variation at the MC4R gene locus contributed to the propensity to be sedentary.
However, the authors did not adjust for multiple comparisons, thus these associations may be
spurious (43).
Braun et al (7) examined the body composition of MC4R knock out (KO) mice and dietinduced obese mice to investigate the role of melanocortin signaling in regulating the accrual of
lean mass independent from increases in fat mass. MC4R KO mice (8-week-old male, n=13) and
age and weight matched wild type (WT) controls (n=10) were subjected to treadmill running at
escalating speed. Despite only mild differences in body composition, MC4R KO mice showed a
dramatic reduction in treadmill running time and distance covered compared to WT. MC4R KO
mice ran for less than half the time and covered only one third of the distance achieved by the
control group. To determine if a functional deficit in skeletal muscle might be responsible for the
poor exercise endurance phenotype of MC4RKO mice, they also measured grip strength and
found that it was slightly increased in MC4RKO mice relative to WT mice. These data suggest
that melanocortin signaling plays a fundamental role in determining skeletal muscle function.
Investigators concluded that inability to achieve peak exercise-induced cardiac output underlies
the exercise phenotype of the MC4R KO mouse.
As shown, FTO (rs9939609) and MC4R (rs17782313) are reported to associate with PA
in other cohort, and also appears to have biological plausibility to associate with PA. To date,
there are no studies that examine if TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1
(rs7498665), and KCTD15 (rs11084753) associate with PA in humans. However, Negr1 and its
association with PA have been examined with mice (36).
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Genetic variants associate with obesity that is biologically plausible to affect PA level
Neuronal growth regulator 1 (NEGR1)
NEGR1 is located on 16q12.2, and encodes a cell adhesion molecule of the
immunoglobulin (Ig) superfamily that belongs to the IgLON subgroup (37). Proteins belonging
to this family influence guidance of neurons to their appropriate targets and their activities
depend upon the type of IgLON protein expressed by neurons. Founding members of this protein
family are limbic system-associated membrane protein (LSAMP), a 64-68 kDa (338 amino
acids) neuronal surface glycoprotein distributed in the cortical and subcortical regions of the
limbic system (49). Notably, anatomy of dopaminergic pathway begins in the ventral tegmental
area of the midbrain and connects to the limbic system via the nucleus accumbens, the amygdala,
and the hippocampus as well as to the medial prefrontal cortex (PFC) (30).
Orkunoglu-Suer et al. (47) also examined NEGR1 A>G in FAMuSS cohort with its
association with obesity phenotype. They reported that the NEGR1 A>G did not show
association with BMI, subcutaneous fat, and their response to resistance training. However,
GIANT consortium reported that NEGR1 A>G associate with BMI, and more importantly,
NEGR1 has been shown to associate with PA level in vivo.
To characterize the function of NEGR1 for body weight control in vivo, Lee et al (36)
generated two novel mutant mouse lines, including a constitutive NEGR1-deficient mouse line
as well as an ENU-mutagenized line carrying a loss-of-function mutation (Negr1-I87N) and
performed metabolic phenotypic analyses. Negr1-I87N mutants display reduced food intake.
Also, Negr1-I87N mutants displayed overall reduction in PA as measured by the number of
breaks in infrared beams, average speed of movements, and total distance travelled within 24 hr
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in a photo beam-based activity monitoring system, consistent with the reduced energy
expenditure before normalization (36).
NEGR1 and its association with PA may be explained via NEGR1’s influence on the
limbic system-associated membrane protein (LSAMP). Limbic system is involved in motivation,
emotion, learning, and memory, and is highly interconnected with the nucleus accumbens, the
brain's pleasure center. And, these responses are heavily modulated by dopaminergic projections
from the limbic system. Innos et al (25) investigated changes in major monoamine systems in
mice lacking the Lsamp gene. Lsamp–/– and Lsamp+/+ mice were randomly divided into groups
that received an injection of either saline or 5 mg/kg of amphetamine. They observed a
significant genotype effect on the content of dopamine in dorsal striatum (F(1,19) =5.67, p <0.05),
mesencephalon (F(1,19) =4.9, p <0.05), and prefrontal cortex (F(1,20) =8.2, p <0.01) . More
importantly, Lsamp gene KO animals showed profound change in sensitivity to the locomotor
and rewarding effects of amphetamine (25). In the amphetamine dose curve study, distance
travelled was significantly influenced by genotype (F(1,40) =16.25, p <0.001), dose (F(3,40) =22.07,
p <0.001), and genotype × dose interaction (F(3,40) =8.47, p <0.001), Lsamp–/– mice being
significantly less sensitive to the stimulating effect of 5 mg∙kg-1 and 7.5 mg∙kg-1 of amphetamine.
With all combined, genetic variants in NEGR1 may have impact on dopaminergic pathway via
LSAMP alteration, which has shown to associate with PA.
Src homology 2 B adapter protein 1 (SH2B1)
SH2B1 gene is located on chromosome 16p11.2. SH2B1 is a member of the SH2B family
of adaptor proteins that includes SH2B1, SH2B2, and SH2B3. Alternative splicing gives rise to
α, β, γ and δ isoforms of SH2B1. These multiple isoforms of SH2B1 are expressed in the brain,
which suggests that centrally expressed SH2B1β is critical to energy homeostasis. SH2B1
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isoforms are recruited, through their SH2 domain, to the activated form of cytokine receptorassociated JAK tyrosine kinases and multiple receptor tyrosine kinases. Influence of SH2B1 on
tyrosine kinases enables them to serve as an adaptor and/or scaffolding protein for multiple
hormones and growth factors, including growth hormone, insulin, leptin, insulin-like growth
factor-1, and nerve growth factor (50, 52, 57, 65).
Orkunoglu-Suer et al. (47) also examined NEGR1 A>G in FAMuSS cohort with its
association with obesity phenotype. They reported that NEGR1 A>G was associated with less of
a difference in subcutaneous fat volume using a dominant model after the 12-week training
period [AG/GG (n=191): 9,813±2,250 mm3 vs AA (n=126) 770±2,772 mm3; p=0.011). This
SNP explained 2.0% of the phenotype in women.
Notably, SH2B1 is a key endogenous positive regulator of leptin sensitivity. Targeted
deletion in mice results in impaired leptin signaling and severe obesity (53). Leptin is an
adipocyte-derived cytokine that can act in the brain to suppress feeding and maintain energy
homeostasis. Additionally, leptin activates its receptors in the ventral tegmental area, a critical
site for neuroadaptations to rewarding stimuli, to modulate reward-seeking behaviors. As noted
earlier, Walsh et al (64) reported leptin and leptin receptor genetic variants associate with
habitual PA among European-American adults in FAMuSS cohort (men=111, women=131, 23.4
± 5.4 yr, 24.4 ± 4.6 kg·m-2). Likewise, Bünger et al. (8) reported that lines of mice selectively
bred for either high or low body fat also showed large differences in circulating leptin levels in
comparison with each other and with a control line that showed intermediate leptin levels.
Furthermore, Girard et al. (23) investigated whether circulating leptin levels have been altered in
mice selectively bred for high voluntary wheel‐running activity. They found that serum leptin
levels (ng/mL; log10 transformed for analyses) were significantly lower in high-runner mice than
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in controls. Leptin levels ranged from 1.5 to 3.5 ng/mL in HR and from 1.6 to 7.3 ng/mL in
controls. Taken together, SH2B1 genetic variant may have a potential influence on the
dopaminergic system via altering leptin sensitivity. Since the dopaminergic pathway has been
identified as the putative pathway that governs PA participation, these associations may
influence PA as well.
Potassium channel tetramerization domain containing 15 (KCTD15)
KCTD15 is located on chromosome 19q13.11. In 2009, KCTD15 was identified by Hotta
et al in humans as a BTB domain-containing protein of unknown function (24).
Orkunoglu-Suer et al. (47) also examined KCTD15 G>A in FAMuSS cohort with its
association with obesity phenotype, but did not report any association with BMI, subcutaneous
fat, or their response to resistance training. However, GIANT consortium reported that KCTD15
G>A associate with BMI, and more importantly, functional study that examined KCTD15
indicates that the protein product of the gene may have influence on dopaminergic pathway.
Dutta et al (18) conducted an in vivo study to investigate the physiological function of
KCTD15. They showed that KCTD15 has an inhibitory role on Wnt/β-catenin signaling path
way, which controls communication between cells in the embryo and adult (i.e., cell proliferation
and differentiation during development and healing) (42). As previously noted, the dopaminergic
pathway is the putative biological pathway that modulates motivation to engage in PA.
Interestingly, studies have shown that activation of the Wnt/β-catenin pathway contributes to
increased dopamine neurogenesis during development. That is, β-catenin promotes midbrain
dopaminergic neurogenesis in vivo (27) and the stabilization of β-catenin in ventral
mesencephalic precursors leads to an increase in dopamine differentiation (12, 62). While there
is insufficient literature examining the functional relevance of KCTD15 and obesity, the
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influence of KCTD15 on dopamine neuron via the Wnt/β-catenin pathway may have an
implication on previous findings by GIANT consortium (66) with KCTD15 genetic variants and
BMI. That is, genetic variants in KCTD15 gene may alter differentiation of dopamine neuron via
Wnt/β-catenin pathway, which may eventually influence an individuals’ reward or pleasure from
energy intake (i.e., eating) or energy expenditure (i.e., PA).
Transmembrane protein 18 (TMEM18)
Although previously noted SNPs have been reported to associate with energy intake or
eating behavior, Rask-Andersen et al (51) reported that TMEM18 does not associate with eating
behavior. However, due to its association with dopaminergic pathway, it was selected as the
candidate SNP.
The TMEM18 gene is located on chromosome 2p25.3, and it codes for a highly
conserved transmembrane protein containing three membrane-spanning regions containing a
nuclear localization signal at the C-terminal (2). It most likely localizes to the nuclear membrane
after translation, and was discovered to be involved in the migration of neural stem cells (2).
Rask-Andersen et al (51) used a rodent food choice paradigm to identify associations
between hypothalamic gene expression levels and food intake, as well as body weight of rats
(n=36, 10 wk old). They observed no correlation for TMEM18 expression with high-fat diet
preference, amount of chow, amount of total food ingested, or body weight in the hypothalamus,
nucleus accumbens, amygdala or hippocampus. They also conducted linear regression analysis
of mRNA expression of TMEM18 in regions of the brain in rats as measured by quantitative
reverse transcriptase PCR. They reported a strong correlation (r=0.5694, p=0.0003) between
TMEM18 expression and body weight in the rats’ prefrontal cortex (PFC).
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The PFC has been proposed to have an important role in integrating behavioral cues from
multiple sources in the brain (46). In particular, the dopamine neurons in the ventral tegmental
area and PFC are thought to be very important in the reward-driven behavior-induced process by
the drugs of addiction (4, 5). Evidence has shown that the firing activities of tegmental area
dopamine neurons and addictive behavior of the animals are believed to be controlled by the
glutamatergic synaptic inputs from PFC (17, 21). Involvement of TMEM18s in neural migration
may be a valuable lead, pointing to a role in the development of the PFC. That is, altered PFC
neural development due to a TMEM18 genetic variant may influence the dopaminergic pathway.

Conclusion
Genetic variants that associate with obesity may be appropriate candidate genes to further
investigate for their association with habitual PA level. Present study hypothesized that six SNPs
reported to associate with obesity in GWAS would also associate with PA level in FAMuSS
cohort. Among the six SNPs, MC4R (rs17782313) and FTO (rs9939609) are previously reported
to associate with PA level. Although TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1
(rs7498665), and KCTD15 (rs11084753) have not been investigated with its association with PA
in human, existing literature that examined the function of these SNPs or protein the gene codes
for indicate that these SNPs have biological plausibility to associate with PA.
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Figure 1. Major mechanisms and factors determining energy balance (38)
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Figure 2. Highly simplified schematic diagram showing the multiple neural systems and pathways controlling food intake, energy expenditure, and
energy balance, with emphasis on interactions between metabolic, cognitive, and rewarding brain systems (38)
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Chapter 3 – Methods
Overview
This substudy is part of a larger study entitled, Functional Single Nucleotide Polymorphisms
Associated with Human Muscle Size and Strength (FAMuSS, NIH R01 NS40606-02). FAMuSS
is the first systematic study to examine how physiological responses to resistance training are
modified by genes and the environment (11). The FAMuSS database consists of 1219 individuals
(509 males, 708 females) between the ages of 18 to 39 yr who were genotyped for over 400
single nucleotide polymorphisms (SNPs). This substudy is comprised of 535 young, normal
weight men and women [23.4±0.2 yr; body mass index (BMI): 24.6±0.2 kg∙m-2] who completed
the Paffenbarger Physical Activity Questionnaire (PPAQ) (9). FAMuSS was conducted by the
Exercise and Genetics Collaborative Research Group consisting of researchers from the
University of Connecticut, Dublin City University, University of Massachusetts, Central
Michigan University, University of Central Florida, Florida Atlantic University, West Virginia
University, Yale University, Hartford Hospital, and the Children's National Medical Center. The
institutional review boards from the ten institutions involved with FAMuSS approved the study
protocol.
The experimental design of FAMuSS has been described elsewhere (8, 10-12). The
purpose of this study is to identify genetic variants associated with PA that have already been
identified to associate with obesity in genome wide association studies (GWAS) (4).

Subjects
Potential study participants were recruited from the eight resistance training sites via strategic
flyer placement and in-house listserv and radio announcements. Subjects were excluded if they
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were: <18 or >40 yr old, if they were taking any medications known to affect skeletal muscle
function such as corticosteroids, antihypertensive or anti-lipidemic medications, anabolic
steroids, diuretics, arthritis medications (Vioxx, Celebrex), Depo-Provera contraceptive
injection, nasal inhalers (Clenbuterol and Rhinocort), lithium, or chronic use of non-steroidal
anti-inflammatory drugs. In addition, individuals who reported regular participation in resistance
training within the past 12 months prior to enrollment or performed occupational or recreational
PA that involved heavy use of the upper body were also excluded.
As part of the enrollment process subjects completed the PPAQ (Appendix A) and had their
height (in) and body weight (lbs) measured to calculate BMI (kg·m-2). FAMuSS participants
completed the PPAQ and were genotyped for the SNPs Melanocortin 4 receptor (MC4R;
T2745C; rs17782313), Transmembrane protein 18 (TMEM18; rs6548238), Fat mass and
obesity-associated gene (FTO; rs9939609), Neuronal growth regulator 1 (NEGR1; rs2815752),
Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; rs7498665), and Potassium channel
tetramerisation domain containing 15 (KCTD15; rs11084753). Subjects who were genotyped for
above SNPs comprised a sample of 492 individuals (230 males, 265 females) for this sub-study.

Body Composition
Anthropometric measures were collected using standardized protocols among the testing sites.
Height and weight were measured using a calibrated wall-mounted stadiometer and scale,
respectively, from which BMI was calculated (kg∙m-2).

Physical Activity
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Subjects completed the PPAQ during their initial visit to assess weekly PA over last year. The
PPAQ is a validated eight-item instrument used to measure self-reported weekly duration and
intensity of PA (6). The PA phenotypes reported in this study were those that showed statistical
significant associations with the genotypes. The extracted PPAQ phenotypes were: total PA
index (kcal∙wk-1), energy expended in moderate and vigorous intensity PA (kcal∙wk-1), energy
expended in sport or recreation (kcal∙wk-1), and time spent in light, moderate, and vigorous
intensity PA, and sitting (hr∙wk-1). The PA phenotypes derived from the PPAQ questionnaire is
described in greater details in Appendix C.

Selection of Genetic Variants
As one of the expected phenotypic outcomes of being physically inactive is gaining weight,
SNPs reported to associate with obesity phenotype in GWAS may also associate with habitual
PA among FAMuSS cohort. Thus, the purpose of this sub-study was to examine all SNPs
reported in GWAS published to date that associate with obesity phenotypes, and that were
genotyped in the FAMuSS data set. To this end, we used the systematic search strategy of Fall
and colleagues (2012) and expanded the date of their systematic search (2012/03/01). Their
search terms included: (‘‘Genome-Wide Association Study’’ [Mesh] OR ‘‘genome wide’’ OR
‘‘whole-genome’’) AND (‘‘Obesity’’ [Mesh] OR ‘‘Body Mass Index’’ [Mesh] OR ‘‘Body Fat
Distribution’’ [Mesh] OR ‘‘Metabolic Syndrome X’’ [Mesh] OR ‘‘Waist–Hip Ratio’’ [Mesh]
OR ‘‘Waist Circumference’’ [Mesh] OR ‘‘waist circumference’’ OR ‘‘body fat percentage’’ OR
‘‘fat mass’’) with the limits: Humans, English and Publication Date from 2006/01/01 to
2012/03/01. They have previously identified 99 SNPs that associated with obesity phenotypes,
and no additional SNPs were reported to associate with obesity phenotype.
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Of the 99 SNPs identified by Fall et al. (2012), FAMuSS had genotype information on six of
these SNPs that included are included in this substudy: MC4R (rs17782313) and FTO
(rs9939609), TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15
(rs11084753) (Table 1).
Table 1. Chi-square (χ2) and allelic frequencies of single nucleotide polymorphisms examined in
the current study.
Nearest Gene
RefSeq#
Alleles(+/-)
χ2
p
q
p-value
FTO
rs9939609
T/A
0.74
0.40
0.60
0.39
MC4R
rs17782313
T/C
0.04
0.21
0.79
0.83
NEGR1
rs2815752
A/G
0.71
0.65
0.35
0.39
SH2B1
rs7498665
A/G
0.04
0.61
0.39
0.84
KCTD15
rs11084753
G/A
0.02
0.66
0.34
0.88
TMEM18
rs6548238
C/T
0.08
0.82
0.18
0.78
FTO, Fat mass and obesity-associated gene; Melanocortin 4 receptor, MC4R; Neuronal growth
regulator 1, NEGR1; Potassium channel tetramerisation domain containing 15, KCTD15; Src
homology 2 B adapter protein 1, SH2B1; Transmembrane protein 18, TMEM18
df=1 for all analyses.
a
p-value <0.05 = Not consistent with Hardy-Weinberg equilibrium.

Genotyping
A sample of whole blood was obtained from each subject, refrigerated, and sent to the
Children’s National Medical Center Research (Washington, DC) where the DNA was extracted
using the Puregene Whole Blood DNA Isolation kit (Gentra Systems, Inc., MN). Genomic DNA
was isolated from peripheral blood lymphocytes with the Gentra Puregene DNA extraction kit
(Qiagen, Valencia, CA) and genotyping was completed using Taqman assays from ABI (Foster
City, CA) according to the manufacturer’s instructions (see Table 2 for assay IDs). Both alleles
for each genetic variant were detected simultaneously using allele-specific oligonucleotides
labeled with different fluorophores. Allele-specific PCR reactions for each polymorphism
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included 20 ng genomic DNA, 900 nM forward and reverse PCR primers, 200 nM fluorescent
allele discrimination probes (common allele FAM labled; rare allele VIC labeled) and TaqMan®
Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems, Foster City, CA, USA)
in a final volume of 25 μl. The PCR and fluorescent ratio profile was generated after 10 minutes
at 95°C (denaturation), 44 cycles of 15 seconds at 92°C and 1 minute at an annealing
temperature of 60°C. The end point fluorescent readings were analyzed using an ABI 7900HT
and the two alleles are called using Sequence Detection System (SDS V 2.3 software; Applied
Biosystems, Foster City, CA) and checked manually. The common allele frequencies for our
population of European-derived Americans were very similar to the allele frequencies reported in
the HapMap (7) (Table 3).

Table 2. Genotyping assays for GWAS-discovered obesity susceptibility SNPs
Nearest gene
RefSeq#
Assay ID a
FTO
rs9939609
C__30090620_10
MC4R
rs17782313
C__32667060_10
NEGR1
rs2815752
C__26668839_10
SH2B1
rs7498665
C__25999166_10
KCTD15
rs11084753
C__31497814_10
TMEM18
rs6548238
C__29311887_10
FTO, Fat mass and obesity-associated gene; Melanocortin 4 receptor, MC4R; Neuronal growth regulator
1, NEGR1; Potassium channel tetramerisation domain containing 15, KCTD15; Src homology 2 B
adapter protein 1, SH2B1; Transmembrane protein 18, TMEM18; GWAS, genome-wide association
study; SNP, single-nucleotide polymorphism.
a
From Applied Biosystem website

Data Administration
Data from all FAMuSS investigative sites were compiled in a Health Insurance Portability and
Accountability Act compliant master database maintained by a statistical consultant at the
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Children's National Medical Center (Washington, DC). Each investigative site manually entered
the FAMuSS data via a secure intranet using a confidential username and password. The PPAQ
from each site was transferred to the University of Connecticut and entered by trained research
assistants into a web-based data entry form
(http://www.education.uconn.edu/surveys/paffenbarger/index2.cfm). For each subject PA
phenotypes were calculated using standard procedures (Appendix A). Any discrepancies that
arouse during data entry of the PPAQ were noted and discussed at weekly research meetings.
Solutions for correcting data were determined by group consensus and the data entry protocol
was amended with the changes.
For example, there were occasions when a less common sport or activity was listed in
question four of the PPAQ. Some activities were not listed in the PA Compendium (1) and
therefore did not have a MET value. A MET value, as previously discussed, is necessary for
calculating the PA phenotypes. In these situations, a similar sport or activity that does appear in
the PA Compendium was used as a substitute. Examples of reported sports/activities not found in
the PA Compendium included dodge ball, Tae Bo, and Dance Dance Revolution. Acceptable
substitutions were determined as racquetball and in the last two examples, “hi-impact aerobics.”
A complete list of substitutions can be found in Appendix B.

Statistical Analysis
Descriptive statistics were calculated for all study variables. Hardy Weinberg Equilibrium was
determined using χ2. Linkage disequilibrium was assessed with r2 to measure pairwise
differences between each pair of SNPs (Table 3), and no SNPs was in linkage disequilibrium
with the other (r2 <0.001). Multivariate analyses of covariance (ANCOVA) tested differences
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among genotypes and PA phenotypes with gender and weight status (normal weight:
BMI<25kg·m-2; overweight: BMI≥25kg·m-2) as fixed factors and age as a covariate. A gender ×
genotype interaction was found with rs2815752 (NEGR1) (p = 0.08), so results are presented for
the total sample and by gender. A weight status × genotype interaction was found with
rs17782313 (MC4R) (p = 0.078) and rs11084753 (KCTD15) (p = 0.055), so results are presented
for the total sample and by weight status. Finally, a gender × weight status × genotype
interaction was observed with rs9939609 (FTO) (p = 0.048), thus results are presented for total
sample and by weight status among men.
When significant main effects were found from the linear multivariate tests (multivariate
ANCOVA), post hoc analyses were performed with Bonferroni adjustments for multiple
comparisons. For these statistical tests, if the homozygous minor group showed a statistically
different phenotype outcome with the heterozygous group and/or homozygous major group, they
were grouped as a recessive model (e.g. T>A, TT/AT vs TT). However, if the homozygous
major group showed a statistically different phenotype outcome with the heterozygous group
and/or homozygous minor group, they were grouped as a dominant model (e.g. T>A, TT vs
AT/TT) (5). The percent variation attributable to genotype was calculated by comparing the full
model [genotype and clinical characteristics (i.e. age, BMI, and gender)] with the constrained
model (clinical characteristics only). The likelihood ratio test was used to test for significance of
these models with linear regression analyses. Only the SNPs that showed statistically significant
associations were presented in the result section.
Epistatic or gene interactions
In order to assess the epistatic or gene x gene interactions on habitual PA, we created an
obesity effect allele score based upon previous GWAS obesity effect alleles reported in the
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literature (4) (Table 2). We then computed a genotype combination score by summing obesity
effect allele to approximate tertiles of the FAMuSS cohort as 1-4 obesity effect allele (n=153;
33.5%), 5-6 obesity effect allele (n=173; 37.9%), and 7-10 obesity effect allele (n=131; 28.7%).
Out of 492 FAMuSS participants in this substudy, 457 subjects were completely genotyped for
all six SNPs and were included in this analysis.
Multivariate ANCOVA tested differences among obesity effect allele groups and PA
phenotypes with gender and weight status as fixed factors and age as a covariate. A gender ×
obesity effect allele group interaction was found with kcal∙wk-1 spent in vigorous intensity PA,
so results are presented by gender. When significant main effects were found for the linear
multivariate tests above (multivariate ANCOVA), post hoc analyses were performed, with
Bonferroni adjustments applied for multiple comparisons. All analyses were performed using the
Statistical Package for the Social Sciences (SPSS) 14.0 for Windows (Chicago, IL, USA) with
the likelihood ratios test as the exception. This analysis was performed with Statistical Analysis
System (SAS) 9.1.3 for Windows (Cary, NC, USA). Statistical significance was established with
alpha set as <0.05.
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Table 3. Genotype frequencies of SNPs for participants in FAMuSS
Alleles
(+/-)

Obesity
effect
allelea

Obesity effect allele
Frequency in FAMuSS
(+)

Published obesity effect
allele frequency for
CEU (+)b

Gene

RefSeq#

MC4R

rs17782313

T/C

T

0.790

0.735

TMEM18

rs6548238

C/T

C

0.824

0.850

FTO

rs9939609

T/A

A

0.395

0.460

NEGR1

rs2815752

A/G

A

0.650

0.637

SH2B1

rs7498665

A/G

G

0.392

0.381

KCTD15

rs11084753

G/A

G

0.664

0.690

CEU, European Caucasian; SNPs, single-nucleotide polymorphisms; FAMuSS, Functional SNPs Associated with Muscle Size and
Strength; CEPH, Center for the Study of Human Polymorphisms; HapMap, haplotype map
MC4R, Melanocortin 4 receptor; TMEM18, Transmembrane protein 18; FTO, Fat mass and obesity-associated gene; NEGR1,
Neuronal growth regulator 1 ; SH2B1, Src homology 2B adapter protein1; KCTD15, Potassium channel tetramerisation domain
containing15
a
According to Willer et al. (13). bUtah residents with northern western European ancestry from the CEPH collection used in
HapMap
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Appendix C. Description of PPAQ phenotypes
Distance walked per week (mile∙wk-1)
Question one was used to calculate distance walked per week. Question one asks “how many city
blocks or their equivalent do you normally walk each day?” (12 blocks = 1 mile). Thus, the
reported distance walked per week (in miles) was calculated by multiplying the number of blocks
walked per day by seven and divided by 12.

Total PA index (kcal∙wk-1)
The PA index was derived from questions one, three and four. Question one determined the
calories expended per week by walking. The total number of blocks walked per week was
multiplied by eight to calculate the caloric expenditure (kcals) (1 block = 8 kcal) (9). Question
three asks, “how many flights of stairs do you climb up each day?” (1 flight= 10 steps). The
calories expended per week by stair climbing was calculated by multiplying the total flights per
week (flights per day x 7) by four (1 flight of stairs = 4 kcal) (9). Question four asks subjects to
“list any sports or recreation you have actively participated in during the past year. It also asks
subjects to describe for each activity the number of times per year they have participated, the
average time spent per bout and years of participation. Each activity listed in question four was
cross-referenced with the PA compendium (2) to determine its absolute intensity, expressed as
metabolic equivalent (MET) value. Intensity can vary across activities and sports and are usually
not objectively measured in habitual PA. The compendium assigns the activity an intensity unit
(MET), which can then be used to estimate the caloric expenditure (kcals) associated with it. A
MET is described as the energy expended during quiet rest and for an adult expressed as 3.5 mL
of oxygen·kg-1 body weight·min-1 (1). This estimation is based on a 70 kg man and thus, may not
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accurately reflect the caloric expenditure for a woman or individuals with a different body
weight. Therefore a correction factor can be used to improve precision (1). Using this
information, calories expended per week in each of the activities listed in question four was
calculated using the following equation:
MET value x 1.225 x total minutes x times per yr/52(days/wk) (3)
Thus, the PA index was calculated by combining total calories expended walking, climbing
stairs, and activities listed in question four.

Energy expended in moderate and vigorous intensity PA (kcal∙wk-1)
Activities listed in question four with a MET value ranging from three to six determined the
calories expended per week performing moderate intensity PA. All activities listed in question
four with a MET value greater than six determined the calories expended per week while
performing vigorous intensity PA. Calories expended per week performing vigorous and
moderate, and sporting activity were calculated using the same methods and equation described
above.

Energy expended in sport or recreation (kcal∙wk-1)
All of the activities listed in question four, regardless of their MET value, were used to determine
the calories expended per week for sport or recreation activity.

Time spent in light, moderate, and vigorous intensity PA, and sitting (hr∙wk-1)
The time spent per week performing vigorous, moderate and light intensity PA as well as time
spent sitting were determined by question eight. Subjects were asked to enter the amount of time
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spent per typical week day and weekend day in each of the four categories. The reported amount
of time in each category must add up to 24 hrs for both weekday and weekend. For question
eight the PPAQ equates vigorous intensity activity to “digging in garden, strenuous sports,
jogging, aerobic dancing, sustained swimming, brisk walking, heavy carpentry, bicycling on
hills, etc.” Moderate intensity activity is equivalent to “housework, light sports, regular walking,
golf, yard work, lawn mowing, painting, repairing, light carpentry, ballroom dancing, bicycling
on level ground, etc.” Light intensity activity is equivalent to “office work, driving a car,
strolling, standing with little motion, etc.” Lastly, sitting activity included “eating, reading, desk
work, watching TV, listening to radio, etc.”
The hours per day spent in vigorous, moderate, light intensity PA and sitting activity were
converted to hours per week using the following equations:
Time spent/wk performing vigorous activity = (hours/weekday∙5) + (hours/weekend day∙2)
Time spent/wk performing moderate activity = (hours/weekday∙5) + (hours/weekend day∙2)
Time spent/wk performing light activity = (hours/weekday∙5) + (hours/weekend day∙2)
Time spent/wk sitting = (hours/weekday∙5) + (hours/weekend day∙2)

72

References
1. Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a
second update of codes and MET values. Med Sci Sports Exerc. 2011; 43(8):1575-81.

2. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of
activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32(9 Suppl):S498-504.

3. Bibi KW, Niederpruem MG. ACSM's Certification Review. 3rd ed. Baltimore, MD: Lippincott
Williams & Wilkins; 2009. 320 p.

4. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syndrome. Mol
Cell Endocrinol. 2012; In Press,(Corrected proof,):doi: 10.1016/j.mce.2012.08.018.

5. Gordish-Dressman H, Devaney JM. Statistical and Methodological Considerations in Exercise
genomics. In: Pescatello LS, Roth SM, editors. Exercise Genomics. New York: Springer Science
Business Media; 2011, p. 23-44.

6. Harris JK, French SA, Jeffery RW, McGovern PG, Wing RR. Dietary and physical activity
correlates of long-term weight loss. Obes Res. 1994; 2(4):307-13.

7. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;
437(7063):1299-320.

8. Kostek MC, Devaney JM, Gordish-Dressman H, et al. A polymorphism near IGF1 is
associated with body composition and muscle function in women from the Health, Aging, and
Body Composition Study. Eur J Appl Physiol. 2010; 110(2):315-24.
73

9. Paffenbarger RS,Jr, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in
college alumni. Am J Epidemiol. 1978; 108(3):161-75.

10. Pescatello LS, Kostek MA, Gordish-Dressman H, et al. ACE ID genotype and the muscle
strength and size response to unilateral resistance training. Med Sci Sports Exerc. 2006;
38(6):1074-81.

11. Thompson PD, Moyna N, Seip R, et al. Functional polymorphisms associated with human
muscle size and strength. Med Sci Sports Exerc. 2004; 36(7):1132-9.

12. Walsh S, Haddad CJ, Kostek MA, et al. Leptin and leptin receptor genetic variants associate
with habitual physical activity and the arm body composition response to resistance training.
Gene. 2012; 510(1):66-70.

13. Willer CJ, Speliotes EK, Loos RJF, et al. Six new loci associated with body mass index
highlight a neuronal influence on body weight regulation. Nat Genet. 2009; 41(1):25-34.

74

Chapter 4 Results
Overview
To date, there are 99 genetic variants reported to be associated with the obesity phenotype in
genome wide association studies (GWAS) (3). The present substudy derived from Functional
Single Nucleotide Polymorphisms Associated with Human Muscle Size and Strength (FAMuSS,
NIH R01 NS40606-02) had genotype information for six of these SNPs: Melanocortin 4
receptor (MC4R; T2745C; rs17782313), Transmembrane protein 18 (TMEM18; rs6548238), Fat
mass and obesity-associated gene (FTO; rs9939609), Neuronal growth regulator 1 (NEGR1;
rs2815752), Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; rs7498665), and
Potassium channel tetramerisation domain containing 15 (KCTD15; rs11084753). These six
variants were tested for associations with PA phenotypes among the FAMuSS cohort.
Subject Characteristics
The sample consisted of healthy, young, normal weight European-American men and women
[Table 1]. While age did not differ by sex (p≥0.05), men had a higher body mass index (BMI)
than women (p<0.001). The sample’s voluntary PA level of 1633.4 ± 102.3 kcal·wk-1 was in the
range recommended by the American College of Sports Medicine for weight gain prevention (2).
In addition, the self-reported sitting time of 6.4 hr∙wk-1 or 40% of waking time among this
FAMuSS subsample was slightly lower than the average American adults’ sitting time (i.e. 60%
of waking time) (1).
Obesity Genotype and PA Energy Expenditure Phenotype (kcal·wk-1) Associations
Three of the six SNPs associated with the PA energy expenditure phenotypes (kcal·wk-1) [Table
2]. Specifically, subjects who were normal weight (BMI<25kg·m-2) carrying the MC4R
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Table 1. Subject Characteristics and Self-reported Physical Activity Levels
Characteristics

Total Sample
(n=495)

Women
(n=265)

Men
(n=230)

Age (yr)

23.5 ± 0.3

23.2 ± 0.4

23.9 ± 0.4

BMI (kg·m-2) a

24.6 ± 0.2

23.9 ± 0.3

25.4 ± 0.3

Total PA Index (kcal·wk-1)

2845.5 ± 117.5

2779.0 ± 138.7

2921.9 ± 196.0

Sports and Recreation (kcal·wk-1)

1633.4 ± 102.3

1621.5 ± 127.1

1647.0 ± 164.7

Vigorous Intensity PA (kcal·wk-1)

1008.6 ± 86.5

937.3 ± 97.4

1090.4 ± 148.6

Moderate Intensity PA (kcal·wk-1)

542.7 ± 47.6

622.2 ± 75.8

451.5 ± 53.3

Vigorous Intensity PA (Hr·wk-1)

8.2 ± 0.4

8.2 ± 0.4

8.2 ± 0.6

Moderate Intensity PA (Hr·wk-1)

20.8 ± 0.6

21.1 ± 0.8

20.6 ± 0.9

Light Intensity PA (Hr·wk-1)

36.7 ± 0.7

37.4 ± 0.9

35.8 ± 1.1

Sitting (Hr·wk-1)

44.7 ± 0.82

43.9 ± 1.0

45.5 ± 1.6

PA phenotype

Values are presented as mean ± standard error
BMI, body mass index; PA, Physical activity
a
p=0.001 (Women vs Men) from independent t-tes

T allele reported expending 1981.2 ± 741.7 kcal∙wk-1 less than non-carriers in the total PA index
(p=0.008), 1825.9 ± 650.2 kcal∙wk-1 less in sports and recreation (p=0.027), and 1231.3 ± 552.7
kcal∙wk-1 less in vigorous intensity PA (p=0.005). The MC4R (rs17782313) T allele explained
1.4 % (p=0.037) of the variability in the total PA index, 1.4% (p=0.035) in sports and recreation,
and 0.7% (p=0.141) in vigorous intensity PA among subjects who were normal weight.
Subjects carrying the TMEM18 (rs6548238) C allele reported expending 1216.5 ± 356.3
kcal∙wk-1 less than non-carriers in moderate intensity PA (p=0.001). The TMEM18 C allele
explained 0.9% (p=0.037) of the variability in moderate intensity PA.
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Men who were overweight (BMI≥25kg·m-2) and homozygous for the FTO (rs9939609) T
allele reported expending 871.4 ± 397.1 kcal∙wk-1 less than A allele carriers in vigorous intensity
PA (p=0.031). The FTO T allele explained 4.8% (p=0.028) of the variability in vigorous
intensity PA among men who were overweight.

Obesity Genotype and PA Time Phenotype (hr·wk-1) Associations
Three of the six SNPs were found to be associated with the PA time phenotypes (hr·wk-1)
[Table 3]. Specifically, subjects homozygous for the SH2B1 (rs7498665) G allele reported
spending 4.8 ± 1.9 hr∙wk-1 less than non-carriers in moderate intensity PA (p=0.013), and 5.6 ±
2.2 hr∙wk-1 more in light intensity PA. The SH2B1 (rs7498665) G allele explained 1.7%
(p=0.013) of the variability in time spent in moderate intensity PA, and 3.5% (p=0.034) of the
time spent in light intensity PA.
Women homozygous for the NEGR1 (rs2815752) G allele reported spending 7.6 ± 2.7
hr∙wk-1 less than A allele carriers in moderate intensity PA (p=0.006). The NEGR1 (rs2815752)
G allele explained 2.6% (p=0.0097) of the variability in time spent in moderate intensity PA
among women.
Subjects who were overweight (BMI≥25kg·m-2) and homozygous for the KCTD15
(rs11084753) A allele reported spending 14.2 ± 4.8 hr∙wk-1 more than G allele carriers in sitting
(p=0.004). The KCTD15 (rs11084753) A allele explained 4.7% (p=0.004) of the variability in
time spent in sitting among subjects who were overweight.
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Table 2. Single Nucleotide Polymorphisms Associations with the Physical Activity Energy Expenditure Phenotypes (kcal·wk -1)
Polymorphism

Phenotype

MC4R
(rs17782313)

Normal weight (BMI<25 kg·m-2)

Total

Overweight (BMI≥25 kg·m-2)

TT/CT(n=458)

CC(n=22)

TT/CT(n=296)

CC(n=16)

TT/CT(n=162)

CC(n=6)

Total PA Index
(kcal·wk-1)

2818.7 ± 121.8

3770.1 ± 557.3

2966.8 ± 158.2

4948.0 ± 724.4a

2598.2 ± 191.9

2337.2 ± 1004.8

Sports and
Recreation
(kcal·wk-1)

1607.6 ± 106.5

2456.2 ± 487.1

1680.1 ± 138.7

3506.0 ± 635.0 b

852.5 ± 138.9

1057.3 ± 727.5

995.3 ± 89.9

1574.7 ± 411.2

1091.6 ± 117.9

2322.8 ± 539.8 c

1491.1 ± 166.0

1371.4 ± 869.5

CC/CT (n=474)

TT(n=16)

CC/CT(n=306)

TT(n=13)

CC/CT(n=168)

TT(n=3)

522.7 ± 51.0

1739.2 ± 352.5 d

529.3 ± 62.6

804.9 ± 304.3

522.3 ± 74.1

2236.4 ± 556.4 e

Vigorous
Intensity PA
(kcal·wk-1)
TMEM18
(rs6548238)
Moderate
Intensity PA
(kcal·wk-1)

Total
FTO
(rs9939609)
Vigorous
Intensity PA
(kcal·wk-1)

Normal weight Men (BMI<25 kg·m-2)

Overweight Men (BMI≥25 kg·m-2)

TT (n=172)

AA/AT (n=311)

TT (n=51)

AA/AT (n=77)

TT (n=51)

AA/AT (n=77)

962.7 ± 164.4

1066.7 ± 113.3

1492.7 ± 348.5

1175.8 ± 283.4

313.3 ± 312.8

1184.7 ± 244.3 f

Values are presented as mean ± standard error adjusted for age
BMI, body mass index; PA, Physical activity
a
p=0.008, b p=0.027, c p=0.005, d p=0.001, e p=0.001, and f p=0.031, (genotype vs genotype) from independent t-test adjusted for age
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Table 3. Single Nucleotide Polymorphisms Associations with Physical Activity Time Phenotypes (hr·wk-1)
Polymorphism

Phenotype

NEGR1
(rs2815752)

Total

Men

Women

AA/AG (n=435)

GG (n=56)

AA/AG (n=201)

GG (n=28)

AA/AG (n=234)

GG (n=28)

21.1 ± 0.6

16.0 ± 0.8

20.9 ± 1.0

18.1 ± 2.7

21.3 ± 0.9

13.7 ± 2.6 a

AA/AG(n=196)

GG(n=30)

AA/AG(n=196)

GG(n=30)

AA/AG(n=217)

GG(n=46)

Time Spent in
Moderate PA
(hr·wk-1)

21.3 ± 0.7

16.5 ± 1.8 b

21.3 ± 1.0

16.8 ± 2.6

21.9 ± 0.9

17.4 ± 1.9 c

Time Spent in
Light PA (hr·wk-1)

35.8 ± 0.9

41.4 ± 2.1 d

35.3 ± 1.2

37.9 ± 3.1

36.1 ± 1.0

43.7 ± 2.2 e

Time Spent in
Moderate PA
(hr·wk-1)
SH2B1
(rs7498665)

Normal weight (BMI<25 kg·m-2)

Total
KCTD15
(rs11084753)
Time Spent in
Sitting (hr·wk-1)

Overweight (BMI≥25 kg·m-2)

GG/AG (n=434)

AA(n=56)

GG/AG (n=282)

AA(n=37)

GG/AG (n=152)

AA(n=19)

44.2 ± 0.9

48.2 ± 2.5

44.3 ± 1.1

43.3 ± 3.0

44.2 ± 1.6

58.5 ± 4.6 f

Values are presented as mean ± standard error adjusted for age
BMI, body mass index; PA, Physical activity
a
p=0.006, b p=0.013, c p=0.031, d p=0.013, e p=0.002, and f p=0.004 (genotype vs genotype) from independent t-test adjusted for age
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Obesity Effect Allele Score and Physical Activity Phenotype Associations
We examined associations among increasing numbers of obesity effect alleles [Table 3 in
chapter 3] (3, 4) and PA level by calculating an obesity effect allele score [Table 4]. Among the
457 subjects genotyped for the six SNPs reported to be associated with obesity in GWAS (3, 4)
among the FAMuSS cohort, 33.5% of the subjects carried 1-4 obesity effect alleles, 37.9% of the
subjects carried 5-6 obesity effect alleles, and 28.7% of the subjects carried 7-10 obesity effect
alleles. Men carrying 5-6 obesity effect alleles expanded 1082.3 ± 447.2 more kcal∙wk-1 in sports
and recreation (p=0.049) and 663.8 ± 418.1 more kcal∙wk-1 in vigorous intensity PA (p=0.049)
[Figure 1] than men carrying 7-10 obesity effect alleles. In addition, men carrying 5-6 obesity
effect alleles had a BMI that was 1.5 ± 0.5 kg∙m2 greater than men with 1-4 obesity effect alleles
(p=0.016). The obesity effect allele score was not associated with any PA phenotypes or BMI
among women or the total sample (p≥0.05).

80

Table 4. Obesity Effect Alleles Score Associations with Physical Activity Energy Expenditure Phenotype (kcal∙wk-1) and Body Mass Index
Men

Total

Women

1-4

5-6

7-10

1-4

5-6

7-10

1-4

5-6

7-10

n=153

n=173

n=131

n=71

n=79

n=58

n=82

n=94

n=73

33.5%

37.9%

28.7%

15.5%

17.3%

12.7%

17.9%

20.6%

16.0%

Total PA Index (kcal·wk1
)

2687.8 ± 212.7

3156.9 ± 199.6

2657.5 ± 229.4

2739.4 ± 362.5

3480.7 ± 342.9

2503.3 ± 409.6

2650.7 ± 281.2

2809.6 ± 250.3

2667.9 ± 285.1

Sports and Recreation
(kcal·wk-1) *

1447.8 ± 184.9

1988.9 ± 173.5

1414.9 ± 199.4

1554.3 ± 303.3

2218.1 ± 287.0

1135.8 ± 342.8a

1401.4 ± 257.1

1683.6 ± 228.9

1578.7 ± 260.8

25.4 ± 0.3

26.1 ± 0.2

26.0 ± 0.3

25.3 ± 0.4

26.8 ± 0.4b

25.8 ± 0.8

25.6 ± 0.4

25.4 ± 0.3

26.2 ± 0.4

Number of Obesity Effect
Allele
Phenotypes

BMI (kg·m-2) *

Values are presented as mean ± standard error adjusted for age
PA, Physical activity; BMI, Body mass index
*p<0.05, analysis from multivariate ANCOVA adjusted from age among men
a
p=0.031, 5-6 vs 7-10 from post-hoc pair-wise comparison bonferroni adjusted following multivariate ANOCOVA
b
p=0.016, 1-4 vs 5-6 from post-hoc pair-wise comparison bonferroni adjusted following multivariate ANOCOVA
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Figure 1. Associations among number of Obesity Effect Allele and kcal∙wk-1 Spent in
Vigorous Intensity Physical Activities and Other Activities

*

Bar displays energy expended in vigorous intensity PA and other activities (mean±SEM).
*p=0.031, 5-6 vs 7-10 from post-hoc pair-wise comparison bonferroni adjusted
Age was a significant covariate in this association.
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Chapter 5. Discussion
We tested six SNPs associated with obesity from GWAS (12) for their association with
PA in the FAMuSS cohort. These SNPs were MC4R (rs17782313) and FTO (rs9939609), widely
reported in the obesity literature; and the newly identified SNPs (43) TMEM18 (rs6548238),
NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 (rs11084753) that have not been studied
in humans regarding their association with PA. We found these six SNPs associated with a
variety of self- reported PA phenotypes. These associations were gender and body weight
dependent and accounted for ~1-5% of the variance in the PA phenotypes. The genotype
differences in energy expenditure ranged from 871 to 1981 kcal∙wk-1 and equated to potentially a
weight gain or loss of 11-25 lb∙yr-1, suggesting our findings have important implications for
weight maintenance.
We also examined gene interactions by summing the number of obesity effect alleles.
Men with 5-6 obesity effect alleles expended 663.8 ± 418.1 more kcal∙wk-1 in vigorous intensity
PA than men with 7-10 obesity effect alleles, with similar non-significant trends noted for 1-4
obesity effect alleles. Also, men carrying 5-6 obesity effect alleles had a BMI that was 1.5 ± 0.5
kg∙m2 greater than men with 1-4 obesity effect alleles, with similar non-significant trends noted
for 7-10 obesity effect alleles. These findings suggest a co-dominant influence of obesity effect
and non-effect alleles positively on vigorous intensity PA and negatively on BMI in the
FAMuSS cohort.
Our findings with MC4R (rs17782313) and FTO (rs9939609) and their associations with
PA confirm prior reports in the literature. Loos et al. (26) examined whether MC4R
(rs17782313) influenced self-reported PA among parents (n=326, 52 ± 3.4 yr) and their offspring
(n=343, 28 ± 8.7 yr) who were overweight in the Quebec Family Study. PA was recorded in a
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three day PA diary with each activity categorized into one of nine PA classes, ranging from
sleep=1 MET to vigorous intensity PA=9 METs. The parents who were homozygous for the
MC4R (rs17782313) T allele reported engaging in 986.1 kcal∙wk-1 less in moderate-to-vigorous
intensity PA than subjects with the CT genotype and 1500.6 kcal∙wk-1 less than the CC genotype,
with these trends most pronounced in adults who were not obese. Similar to Loos et al. (26), we
found body weight dependent associations with MC4R (rs17782313) and PA. That is, FAMuSS
subjects who were normal weight and carried the MC4R (rs17782313) T allele reported
expending 1981.2 ± 741.7 kcal∙wk-1 less than non-carriers in total PA, a genotype difference that
explained 1.7 % of the variance in PA, and potentially could approximate a weight gain or loss
of 25 lb∙yr-1.
Cecil et al. (8) examined 97 Scottish children, 4 to 10 years of age, for possible
association of FTO (rs9939609) with energy expenditure. They measured total energy
expenditure by isotope dilution, resting metabolic rate by indirect calorimetry, and PA was
calculated by subtracting resting metabolic rate from total energy expenditure. Cecil et al. (8)
found children carrying the FTO (rs9939609) A allele expended 160.3 kcal∙wk-1 more than noncarriers. Similarly, we found the FTO (rs9939609) A allele associated with greater energy
expenditure than non-carriers in the FAMuSS cohort. That is, men who were overweight and
carried the FTO (rs9939609) A allele reported expending 871.4 ± 397.1 kcal∙wk-1 more than
non-carriers in vigorous intensity PA, a genotype difference that explained 4.8 % of the variance
in PA, and potentially could approximate a weight gain or loss of 11 lb∙yr-1.
Reports in the literature and our new findings collectively support the notion that obesityrelated genetic variants are plausible candidate genes to examine for their association with PA.
Bouchard (5) has classified obesity genes into five categories: 1) thrifty (low metabolic rate), 2)
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adipogenesis (accumulate more fat), 3) low lipid oxidation (burn less fat), 4) hyperphagic (over
eat), and 5) sedentary (physically inactive), demonstrating the various effects genes can have on
obesity. Among these, hyperphagic and sedentary genes are expressed in the brain and influence
behavior, namely energy intake and expenditure, respectively (5).
The six SNPs we examined have been classified as hyperphagic (3, 8, 22, 30) and are
expressed in the brain, specifically the hypothalamus, where energy homeostasis is regulated
(44). The hypothalamus is the primary output node for the limbic system, which is responsible
for endocrine function and behavior reinforcement. The limbic system has been implicated in the
control of food procurement as an evolutionarily conserved survival mechanism to defend
against famine (23). More, Lenard et al. (23) proposed that the fundamental desire to engage in
PA behaviors likely resides in a neural pathway nearby where energy intake is regulated. Recent
research (17, 19, 24, 25, 32) has indicated the dopaminergic pathway may govern PA
participation because of its central role in motor movement (35), reward (36), learning,
motivation (28), and emotion (37). Further, dopaminergic neurons are located primarily in the
ventral tegmental area of the brain and the hypothalamus. Thus, the inter-connection of common
neural mechanistic pathways between energy intake (hypothalamus) and PA (dopaminergic
pathway) suggest genetic variants associated with obesity and other related transcriptional and
translational regulatory factors may have associations with PA.
Previous studies (18-20, 33) reported neural association between dopaminergic pathway
and PA levels. Knab et al. (17) investigated differences in the central mRNA expression of
dopamine genes [dopamine receptor 1 (Drd1) and tyrosine hydroxylase (TH)] between highly
active and less active male mice. They found the high-activity strain had lower expression of
Drd1 and TH than the low-activity strain (18), meaning the highly active mice had lower
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expression of dopaminergic genes compared to less active mice. Mc4r and Drd1 are coexpressed in neurons located in the nucleus accumbens, part of the ventral tegmental area of the
brain and the hypothalamus (9). Furthermore, overexpression of FTO mRNA in the
hypothalamus is associated with increased levels of TH, an indicator of dopamine production
(40). The common neural influence of MC4R and FTO on dopamine genes TH and Drd1 should
be explored further for their associations with obesity and PA to provide mechanistic insight for
the associations we observed in the FAMuSS cohort.
To our knowledge, this is the first study investigating NEGR1 (rs2815752), KCTD15
(rs11084753), SH2B1 (rs7498665), and TMEM18 (rs6548238) and their associations with PA in
humans. The biological mechanism by which these SNPs may modulate PA is largely unknown.
However, the biological function of the proteins and their involvement in the dopaminergic
pathway may provide insight for future investigation. NEGR1 promotes neurite growth of
hypothalamic neurons (21), and has been shown to be associated with the limbic system
membrane protein (LSAMP) (27). As the limbic system is largely modulated via the
dopaminergic pathway, the influence of NEGR1 on LSAMP may have implications toward
desire to engage in PA. Moreover, Lsamp knockout mice have been shown to display low PA
level in response to injection of drugs containing dopamine (5 mg∙kg-1 of amphetamine)
compared to Lsamp overexpressed mice (16).
KCTD15 is involved in neural crest formation via the Wnt/β-catenin signaling pathway
(11). The Wnt/β-catenin signaling pathway influences dopamine neurogenesis (6, 38). SH2B1
upregulates the production of leptin (34), a hormone that is involved with energy intake, which
in turn activates its receptors in the dopaminergic pathway (13, 39). Of note, Walsh et al. (42)
found leptin and leptin receptor genetic variants associated with self-reported PA among the
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FAMuSS cohort. Finally, TMEM18 is involved in the migration of neural stem cells (2). In rats,
weight gain and overexpression of TMEM18 showed association in prefrontal cortex (31), where
the firing activities in dopamine neurons are controlled via glutamatergic synaptic input (10, 14).
The biological functions of NEGR1, KCTD15, SH2B1, and TMEM18 suggest potential
involvement in the dopaminergic pathway, which has also been shown to have an important role
in PA behavior (18, 20, 33). The common central neural influence of genetic variants associated
with obesity and PA, particularly in the dopaminergic pathway, is worthy of notice and further
investigation.
Our findings with FTO (rs9939609), NEGR1 (rs2815752), SH2B1 (rs7498665) and PA
were gender dependent. Reasons for these associations are unclear. However, estrogen promotes
dopamine sensitivity primarily through increased firing rate of dopamine neuron in the ventral
tegmental area (46). This heightened sensitivity in turn could influence the desire to engage in
PA lending insight into the gender dependent association we observed. At this time, however, the
role of estrogen in PA behavior is purely speculative due to the paucity of data exploring genetic
variants and PA.
We examined gene interactions among the six SNPs and their association with BMI and
PA level in the FAMuSS cohort. We calculated the number of obesity effect alleles for six SNPs
in our cohort that were previously identified by GWAS to associate with obesity (12). Since low
PA level is typically associated with high BMI, we hypothesized that there would be a dose
response decrease in PA level and increase in BMI as the number of obesity effect alleles
increased. However, we observed a co-dominant influence of obesity effect and non-effect
alleles on PA level and BMI. Specifically, men with 5-6 obesity effect alleles expended 663.8 ±
418.1 more kcal∙wk-1 in vigorous intensity PA than men with 7-10 obesity effect alleles, and had
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a BMI that was 1.5 ± 0.5 kg∙m2 greater than men with 1-4 obesity effect alleles, with similar nonsignificant trends noted for 7-10 obesity effect alleles.
Our findings are consistent with the work of Cecil et al. (8) who found genetic
predispositions to high BMI, PA level, and energy intake among Scottish children. They found
children carrying the FTO (rs9939609) A allele had 71.6 kcal∙meal-1 higher energy intake, 0.9
kg∙m2 higher BMI, and 160.3 kcal∙wk-1 higher energy expenditure than non-carriers. According
to the classification scheme of Bouchard (5), obesity genes predispose individuals to obesity via
multiple pathways such as high rate of adiopogenesis, low lipid oxidation, and hyperphagia.
Thus, if high PA level is coupled with obesity genes to offset the energy expenditure, an
individual could express a high BMI despite engaging in more PA than other genotype groups.
The National Weight Control Registry consists of individuals maintaining a weight loss of at
least 13.6 kg (30 lb) for a minimum of 1 year. Although National Weight Control Registry
entrants report an average of 2,621 kcal∙wk-1 in PA, there is considerable variability in the
amount of PA completed, with ~25% reporting <1,000 kcal∙wk-1 and ~50% reporting > 2800
kcal∙wk-1 (7). As shown, some may perform more PA for successful weight loss and/or
maintenance than others, and this variability may explain the genetic predisposition to high BMI
in spite of high PA level reported by Cecil et al. and now by FAMuSS investigators.
The genotype differences in energy expenditure we found that ranged from 871 to 1981
kcal∙wk-1 could theoretically amount to a weight gain or loss of 11 to 25 lb∙yr-1. These clinically
significant outcomes have important implications for public health (45). Furthermore, preference
of vigorous intensity PA was observed among men who were overweight (BMI≥25kg·m-2) and
FTO (rs9939609) A allele carriers, such that they expended 871.4 ± 397.1 kcal∙wk-1 more than
non-carriers in vigorous intensity PA. Thus, when recommending exercise to adults for overall
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health benefits, these exercise intensity preferences due to genotype could be considered when
counseling people to become more physically active due to what appears to be a genetic
predisposition to prefer vigorous over moderate intensity PA among overweight men with the
FTO (rs9939609) A allele carriers. Nonetheless, incorporating genetic information into
personalized exercise prescription in practice remains a vision of the future until scientists
elucidate the complex interconnected influence of genetic factors, clinical factors, and
environment on phenotypes of interest (15).
This study has several limitations. Habitual PA is a complex behavior influenced by
many genetic factors (other than the six SNPs we examined), clinical information (age, BMI, and
gender) and environmental factors (social, built, and natural) (4). The PA data we collected with
the Paffenbarger PA questionnaire are susceptible to subject recall and social desirability bias
(29). However, the Paffenbarger PA questionnaire is a valid and reliable method for assessing
leisure time PA in similar populations to the present study (1). We also did not obtain
mechanistic data or energy intake phenotypes such that our discussion of PA and energy intake
mechanisms is purely speculative. This study has several strengths. We chose candidate SNPs
from a systematic review of obesity-related genetic variants reported in GWAS that had been
genotyped in FAMuSS (12, 44). Furthermore, FAMuSS is recognized as one of the largest
exercise genomics studies conducted [14, 47]. Finally, PA is more heritable among young adults
and tends to decrease with age (41). Therefore, as ~75% of the FAMuSS subjects are 18 to 25
years of age, their PA is likely to exhibit a high level of heritability.
In summary, we have shown that six genetic variants associated with obesity in GWAS
that were genotyped in the FAMuSS cohort also associated with habitual PA. These associations
were gender and BMI dependent, and accounted for ~1-5% of variance of PA level. The
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genotype differences in energy expenditure ranged from 871 to 1981 kcal∙wk-1 equating to a
weight gain or loss of potentially 11-25 lb∙yr-1. Our findings suggest a personalized approach to
weight management is warranted based upon genetic predispositions to habitual PA engagement.
The mechanisms explaining these associations appear to resides in similar central neural
pathways as energy intake (i.e. the dopaminergic pathway) that should be explored further as do
the remaining 93 obesity-related genetic variants in GWAS for their associations with obesity
phenotypes, habitual PA level and energy intake.
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